This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sue Pierce Appointed Vice President, Product Development Of GenMark Diagnostics

GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that it has appointed Ms. Sue Pierce as Vice President, Product Development, effective April 18, 2011.

Ms. Pierce joins the company with extensive diagnostics experience including over 11 years at Ventana Medical Systems (a division of Roche Diagnostics) and over 14 years at Abbott Laboratories. Most recently, Ms. Pierce was Vice President, Project Management Office in charge of all product development and program management processes across Ventana’s product portfolio. Prior to that she held the role of VP/Sr. Director, Integration and Technical Support, where she developed and led a customer-focused Global Product Technical Support function as well as led the R&D integration activities for the Roche acquisition. She was also previously Director, Product Development where she was responsible for numerous product development and system integration teams, as well as the Design Control team lead for re-engineering and implementation of a new quality system.

While at Abbott Laboratories, Ms. Pierce held roles of increasing responsibility in Abbott’s Diagnostics Division, in Clinical Chemistry, Immunochemistry, and Systems Integration functions. Prior to Abbott Laboratories, she held various R&D and Operations technical positions at Celanese Corporation. Ms. Pierce has a BS in Chemistry and an MS in Analytical Chemistry, both from Oklahoma State University.

"We are very pleased to welcome Sue to the GenMark team," said Chris Gleeson, GenMark's Chairman and CEO. "She brings a wealth of extensive and successful product development experience, a key ingredient at this stage of implementing GenMark’s high growth strategy."

About GenMark Diagnostics, Inc.

GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark's XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs